Naodesheng Pills Ameliorate Cerebral Ischemia Reperfusion-Induced Ferroptosis via Inhibition of the ERK1/2 Signaling Pathway
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s443479 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Yong-Yu Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China. Hauptthemen laut MEDLINE: Ferroptosis, Rats, Sprague-Dawley, Reperfusion Injury, MAP Kinase Signaling System. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
- Hunan Provincial Engineering Research Central of Translational Medical and Innovative Drug, The Second Xiangya Hospital of Central South University, Changsha, Hunan, People's Republic of China.
- School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou, Guangdong, People's Republic of China.
ORCID-Profile: Yong-Yu Yang
Zitieren
APA
Yang, Y. Y., Deng, R. R., & Xiang, D. X. (2024). Naodesheng Pills Ameliorate Cerebral Ischemia Reperfusion-Induced Ferroptosis via Inhibition of the ERK1/2 Signaling Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s443479
Vancouver
Yang YY, Deng RR, Xiang DX. Naodesheng Pills Ameliorate Cerebral Ischemia Reperfusion-Induced Ferroptosis via Inhibition of the ERK1/2 Signaling Pathway. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s443479
BibTeX
@article{Yang2024,
author = {Yang, Yong-Yu and Deng, Rong-Rong and Xiang, Da-Xiong},
title = {Naodesheng Pills Ameliorate Cerebral Ischemia Reperfusion-Induced Ferroptosis via Inhibition of the ERK1/2 Signaling Pathway},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s443479}
}
EUVIMED